Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 13, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	7,588	6,083	4,882	7,694	5,659	5,765
Market Cap Growth	-3.81%	24.59%	-36.54%	35.96%	-1.84%	122.48%
Enterprise Value	8,552	6,951	5,929	8,940	5,722	5,817
Last Close Price	64.04	47.81	36.96	56.90	40.21	42.71
PE Ratio	14.87	13.70	17.34	38.06	14.05	44.66
Forward PE	9.75	19.22	19.22	19.22	17.89	25.20
PS Ratio	6.76	5.99	5.89	11.66	12.76	21.54
PB Ratio	22.64	16.72	58.26	45.31	28.73	38.17
P/TBV Ratio	-	-	-	-	28.73	38.17
P/FCF Ratio	13.99	12.99	13.08	32.70	18.99	108.87
P/OCF Ratio	13.80	12.70	12.57	32.04	18.90	103.95
EV/Sales Ratio	7.26	6.85	7.15	13.54	12.91	21.74
EV/EBITDA Ratio	11.27	11.09	14.22	26.60	20.63	39.89
EV/EBIT Ratio	12.53	12.61	17.43	30.89	20.74	40.33
EV/FCF Ratio	15.82	14.84	15.88	37.99	19.20	109.86
Debt / Equity Ratio	4.62	4.22	18.27	9.07	4.47	2.66
Debt / EBITDA Ratio	2.00	2.42	3.59	4.54	3.15	2.71
Debt / FCF Ratio	2.85	3.28	4.10	6.55	2.95	7.59
Asset Turnover	0.59	0.54	0.46	0.45	0.53	0.47
Inventory Turnover	1.56	1.77	2.36	2.67	2.04	1.72
Quick Ratio	6.44	6.50	5.07	4.54	7.10	1.11
Current Ratio	8.36	7.80	6.64	5.65	7.91	1.32
Return on Equity (ROE)	179.14%	198.42%	222.07%	110.23%	231.44%	106.33%
Return on Assets (ROA)	21.21%	18.16%	11.89%	12.28%	20.47%	15.74%
Return on Capital (ROIC)	23.10%	19.61%	12.78%	12.98%	21.16%	17.11%
Return on Capital Employed (ROCE)	35.60%	28.70%	21.00%	16.90%	27.90%	91.00%
Earnings Yield	7.37%	7.30%	5.77%	2.63%	7.12%	2.24%
FCF Yield	7.15%	7.70%	7.65%	3.06%	5.27%	0.92%
Buyback Yield / Dilution	2.50%	3.56%	4.56%	4.21%	-3.77%	1.99%

Updated May 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q